Literature DB >> 21476062

Spontaneous recovery of bone mass after cure of endogenous hypercortisolism.

Maria Elena Randazzo1, Erika Grossrubatscher, Paolo Dalino Ciaramella, Angelo Vanzulli, Paola Loli.   

Abstract

Patients with Cushing's syndrome (CS) develop osteopenia-osteoporosis. The present study evaluates the recovery of bone mass within 2 years after remission of hypercortisolism and in long term follow up, an issue rarely addressed. Twenty patients (6M, 14F, 3 post-menopausal, 15-64 years old), 15 with Cushing's disease, 2 with ectopic ACTH syndrome, 3 with ACTH-independent CS were studied. BMD, T and Z scores at lumbar spine and proximal femur were assessed by dual-energy X-ray absorptiometry before and 7-33 months after treatment of hypercortisolism. Five patients were treated with bisphosphonates. Four patients had hypogonadism and 4 GH-deficiency. At baseline all patients showed osteopenia/osteoporosis and the spine appeared more damaged than the femur; femur BMD was positively related with body mass index (BMI). No correlations were observed between spine and femur bone parameters and duration of disease or severity of hypercortisolism. Bone parameters did not differ in patients with or without GH or other pituitary deficiencies. After cure of hypercortisolism a significant improvement in spine BMD, Z and T scores and in femur Z and T scores was observed with normalization in 3 patients; there was no significant difference in percent improvement between femur and spine. The increase in bone parameters at spine and femur was independent from values at baseline. The percent increase in spine T and Z scores was positively related with time elapsed since cure. Bisphosphonates did not influence the recovery of bone mineralization. In long term follow up, after a median period of 7 years a further improvement in bone density was observed in 100% of patients at spine and in 9/11 at femur, although 8/11 patients still had femoral and/or vertebral T score in the range of osteopenia/osteoporosis. Spontaneous improvement of osteoporosis after cure of hypercortisolism occurs both at spine and femur, is independent from basal conditions and not affected by bisphosphonates. The improvement at spine depends on time since cure.

Entities:  

Mesh:

Year:  2012        PMID: 21476062     DOI: 10.1007/s11102-011-0306-3

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  36 in total

Review 1.  Osteoporosis in Cushing's syndrome.

Authors:  Gregory Kaltsas; Luca Manetti; Ashley B Grossman
Journal:  Front Horm Res       Date:  2002       Impact factor: 2.606

Review 2.  Diagnosis and complications of Cushing's syndrome: a consensus statement.

Authors:  G Arnaldi; A Angeli; A B Atkinson; X Bertagna; F Cavagnini; G P Chrousos; G A Fava; J W Findling; R C Gaillard; A B Grossman; B Kola; A Lacroix; T Mancini; F Mantero; J Newell-Price; L K Nieman; N Sonino; M L Vance; A Giustina; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

Review 3.  Body mass index as a predictor of fracture risk: a meta-analysis.

Authors:  C De Laet; J A Kanis; A Odén; H Johanson; O Johnell; P Delmas; J A Eisman; H Kroger; S Fujiwara; P Garnero; E V McCloskey; D Mellstrom; L J Melton; P J Meunier; H A P Pols; J Reeve; A Silman; A Tenenhouse
Journal:  Osteoporos Int       Date:  2005-06-01       Impact factor: 4.507

4.  Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index.

Authors:  E A Greco; R Fornari; F Rossi; V Santiemma; G Prossomariti; C Annoscia; A Aversa; M Brama; M Marini; L M Donini; G Spera; A Lenzi; C Lubrano; S Migliaccio
Journal:  Int J Clin Pract       Date:  2010-05       Impact factor: 2.503

5.  [Development of bone mineral density after cure of Cushing's syndrome].

Authors:  B Catargi; A Tabarin; B Basse-Cathalinat; D Ducassou; P Roger
Journal:  Ann Endocrinol (Paris)       Date:  1996       Impact factor: 2.478

6.  Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.

Authors:  A R Hermus; A G Smals; L M Swinkels; D A Huysmans; G F Pieters; C F Sweep; F H Corstens; P W Kloppenborg
Journal:  J Clin Endocrinol Metab       Date:  1995-10       Impact factor: 5.958

7.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

8.  Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group.

Authors:  H K Genant; M Jergas; L Palermo; M Nevitt; R S Valentin; D Black; S R Cummings
Journal:  J Bone Miner Res       Date:  1996-07       Impact factor: 6.741

9.  Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome.

Authors:  L Tauchmanova; E Guerra; R Pivonello; M C De Martino; M De Leo; F Caggiano; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  2009-05       Impact factor: 4.256

10.  Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.

Authors:  T P Van Staa; R F Laan; I P Barton; S Cohen; D M Reid; C Cooper
Journal:  Arthritis Rheum       Date:  2003-11
View more
  9 in total

1.  Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

Authors:  A Scillitani; G Mazziotti; C Di Somma; S Moretti; A Stigliano; R Pivonello; A Giustina; A Colao
Journal:  Osteoporos Int       Date:  2013-12-06       Impact factor: 4.507

Review 2.  Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.

Authors:  G Arnaldi; T Mancini; G Tirabassi; L Trementino; M Boscaro
Journal:  J Endocrinol Invest       Date:  2012-04       Impact factor: 4.256

Review 3.  Clinical and biochemical manifestations of Cushing's.

Authors:  Georgia Ntali; Ashley Grossman; Niki Karavitaki
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 4.  Novel approaches to bone comorbidity in Cushing's disease: an update.

Authors:  Stefano Frara; Luigi di Filippo; Mauro Doga; Paola Loli; Felipe F Casanueva; Andrea Giustina
Journal:  Pituitary       Date:  2022-07-18       Impact factor: 3.599

5.  Lower extremity insufficiency fractures: an underappreciated manifestation of endogenous Cushing's syndrome.

Authors:  S Poonuru; J W Findling; J L Shaker
Journal:  Osteoporos Int       Date:  2016-08-15       Impact factor: 4.507

6.  Fracture risk assessment before and after resolution of endogenous hypercortisolism: is the FRAX® algorithm useful?

Authors:  Laura Trementino; Letizia Ceccoli; Carolina Concettoni; Giorgia Marcelli; Grazia Michetti; Marco Boscaro; Giorgio Arnaldi
Journal:  J Endocrinol Invest       Date:  2014-07-11       Impact factor: 4.256

Review 7.  Update on vertebral fractures in pituitary diseases: from research to clinical practice.

Authors:  Flaminia Carrone; Salvatore Ariano; Sara Piccini; Davide Milani; Marco Mirani; Luca Balzarini; Andrea Gerardo Lania; Gherardo Mazziotti
Journal:  Hormones (Athens)       Date:  2021-02-19       Impact factor: 2.885

8.  Assessment of non-traumatic vertebral fractures in Cushing's syndrome patients.

Authors:  T Apaydın; D G Yavuz
Journal:  J Endocrinol Invest       Date:  2021-01-09       Impact factor: 4.256

9.  Metastatic medullary thyroid carcinoma presenting as ectopic Cushing's syndrome.

Authors:  Hannah E Forde; Niamh Mehigan-Farrelly; Katie Ryan; Tom Moran; Megan Greally; Austin G Duffy; Maria M Byrne
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-04-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.